A detailed history of E Fund Management Co., Ltd. transactions in Halozyme Therapeutics, Inc. stock. As of the latest transaction made, E Fund Management Co., Ltd. holds 11,909 shares of HALO stock, worth $543,645. This represents 0.04% of its overall portfolio holdings.

Number of Shares
11,909
Previous 7,954 49.72%
Holding current value
$543,645
Previous $416,000 63.7%
% of portfolio
0.04%
Previous 0.02%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$51.3 - $64.42 $202,891 - $254,781
3,955 Added 49.72%
11,909 $681,000
Q2 2024

Aug 12, 2024

SELL
$37.81 - $52.4 $91,916 - $127,384
-2,431 Reduced 23.41%
7,954 $416,000
Q1 2024

May 13, 2024

SELL
$33.68 - $41.95 $55,167 - $68,714
-1,638 Reduced 13.62%
10,385 $422,000
Q4 2023

Feb 06, 2024

BUY
$33.32 - $42.1 $4,964 - $6,272
149 Added 1.25%
12,023 $444,000
Q3 2023

Nov 13, 2023

SELL
$36.46 - $44.03 $46,595 - $56,270
-1,278 Reduced 9.72%
11,874 $454,000
Q2 2023

Aug 11, 2023

BUY
$30.28 - $38.74 $117,335 - $150,117
3,875 Added 41.77%
13,152 $474,000
Q1 2023

May 11, 2023

BUY
$32.86 - $55.7 $60,791 - $103,045
1,850 Added 24.91%
9,277 $354,000
Q4 2022

Feb 14, 2023

SELL
$40.06 - $59.44 $163,364 - $242,396
-4,078 Reduced 35.45%
7,427 $423,000
Q3 2022

Nov 14, 2022

BUY
$38.53 - $51.78 $57,987 - $77,928
1,505 Added 15.05%
11,505 $455,000
Q2 2022

Aug 15, 2022

BUY
$37.35 - $48.3 $84,933 - $109,834
2,274 Added 29.43%
10,000 $440,000
Q1 2022

May 12, 2022

BUY
$31.97 - $41.06 $86,287 - $110,820
2,699 Added 53.69%
7,726 $308,000
Q4 2021

Feb 11, 2022

BUY
$31.82 - $40.75 $60,521 - $77,506
1,902 Added 60.86%
5,027 $202,000
Q1 2021

May 12, 2021

BUY
$39.51 - $51.45 $123,468 - $160,781
3,125 New
3,125 $130,000

Others Institutions Holding HALO

About HALOZYME THERAPEUTICS, INC.


  • Ticker HALO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 139,288,992
  • Market Cap $6.36B
  • Description
  • Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable...
More about HALO
Track This Portfolio

Track E Fund Management Co., Ltd. Portfolio

Follow E Fund Management Co., Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of E Fund Management Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on E Fund Management Co., Ltd. with notifications on news.